NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Achieve Life Sciences, Inc. (ACHV) Stock Analysis

Achieve Life Sciences, Inc. (ACHV) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ACHV

$6.51

$0.00 (0.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACHV with… →

ACHV Key Statistics

As of Oct 21, 2026
Trading
Open
$6.49
Previous Close
$6.51
Day's Range
6.38–6.67
52-Week Range
2.62–8.64
Volume
2.47M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.31
Valuation
Market Cap
$671.20M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
17.68
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.69
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$54.65M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
103.10M
1-Year Return
+26.41%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.42M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ACHV closed at $6.51, +26.41% over 1 year.

Achieve Life Sciences, Inc. (ACHV) has a market capitalization of $671.20M.

In fiscal 2025, ACHV reported revenue of $0.00.

ACHV Stock Return by Calendar Year

Achieve Life Sciences, Inc. (ACHV) 10-year return: what $10,000 became

1 year
$10,000 $12,641
+26.41%
5 years
$10,000 $8,007
−19.93%
10 years
$10,000 $72
−99.28%

If you had invested $10,000 in Achieve Life Sciences, Inc. (ACHV) 10 years ago, at the close on October 21, 2016, it would have been worth $72 at the close on October 21, 2026: −99.28% in total, −38.93% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+30.99%
2025+41.19%
2024−14.56%
2023+68.16%
2022−68.51%
2021−3.95%
2020−23.58%
2019−56.20%
2018−90.97%
2017−75.64%
2016 (partial year)−43.82%

As of October 21, 2026.

ACHV Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$54.65M—
2024$0.00−$39.83M—
2023$0.00−$29.82M—
2022$0.00−$42.35M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$54.88M−$54.65M—
2024$0.00—−$39.07M−$39.83M—
2023$0.00—−$27.25M−$29.82M—
2022$0.00—−$40.80M−$42.35M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Achieve Life Sciences, Inc. (ACHV) is capitalised at $671.20M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 28 employees.

ACHV last closed at $6.51 on October 21, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $2.62 to $8.64. The latest close sits 148.47% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $54.65M. Earnings per share on a trailing basis come to −1.69.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 17.68.

Beta against the wider market is reported at 2.31. Annualized volatility over the trailing 10 years is 90.48%. The trailing one-year total return is +26.41%. Measured over 10 years, that is −38.93% a year compounded.

Growth & Income

The record shows no dividend for ACHV.

Across the complete calendar years on file, 2023 returned +68.16% and 2018 returned −90.97%. Of the 9 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is +30.99% year to date.

Peer Comparison

Achieve Life Sciences, Inc. (ACHV) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Achieve Life Sciences, Inc. ACHV $671.20M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Achieve Life Sciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

Visit website →